Arcera Life Sciences, a global life sciences company focused on advancing innovative and sustainable healthcare solutions, and Daewoong Pharmaceutical Co., a leading South Korean pharmaceutical company, have announced the expansion of their strategic partnership for Enavogliflozin, Daewoong's novel sodium-glucose cotransporter-2 (SGLT2) inhibitor, into key markets across the Middle East.
The agreement builds upon the successful collaboration established between Daewoong and M8 Pharmaceuticals for Latin America, a partnership that became part of the Arcera platform following Arcera's integration of M8 in December 2024. Since then, Arcera and Daewoong have continued to strengthen their relationship, most recently achieving a significant milestone with the approval of Enavogliflozin in Mexico.
The expansion into the Middle East represents the next phase of the partnership and reflects both companies' shared commitment to increasing patient access to innovative therapies for people living with type 2 diabetes and related cardiometabolic conditions across emerging markets.
Enavogliflozin is a novel SGLT2 inhibitor developed by Daewoong and approved in South Korea for the treatment of type 2 diabetes mellitus. The therapy has demonstrated meaningful efficacy in glycemic control and represents an important addition to the growing range of treatment options available to patients and healthcare professionals globally.
The partnership expansion highlights Arcera's ability to leverage relationships, capabilities, and expertise across its integrated global platform, creating opportunities beyond the original scope of acquired businesses.
